WCM Investment Management LLC Increases Position in Ultragenyx Pharmaceutical Inc. $RARE

WCM Investment Management LLC raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 210,469 shares of the biopharmaceutical company’s stock after purchasing an additional 8,256 shares during the period. WCM Investment Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $7,686,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. CWM LLC increased its position in shares of Ultragenyx Pharmaceutical by 1,171.2% in the 2nd quarter. CWM LLC now owns 4,144 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 3,818 shares during the last quarter. Aberdeen Group plc increased its position in shares of Ultragenyx Pharmaceutical by 4.6% in the 2nd quarter. Aberdeen Group plc now owns 501,056 shares of the biopharmaceutical company’s stock valued at $18,218,000 after purchasing an additional 22,152 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $380,000. KLP Kapitalforvaltning AS increased its position in shares of Ultragenyx Pharmaceutical by 8.6% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 17,700 shares of the biopharmaceutical company’s stock valued at $644,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Ultragenyx Pharmaceutical by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,652 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 557 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $33.97 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $57.97. The stock has a market capitalization of $3.27 billion, a PE ratio of -6.14 and a beta of 0.21. The company has a fifty day moving average of $30.11 and a 200-day moving average of $32.92.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million during the quarter, compared to analysts’ expectations of $161.37 million. During the same quarter last year, the business earned ($1.52) EPS. The business’s revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,942 shares of the firm’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the sale, the chief financial officer owned 98,227 shares in the company, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This trade represents a 3.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,456 shares of company stock valued at $328,486 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

RARE has been the topic of a number of recent analyst reports. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating on the stock in a research report on Thursday, July 10th. Wedbush lowered their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Finally, Guggenheim reissued a “buy” rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.